Zimmer Biomet Holdings Inc (NYSE:ZBH) reached a new 52-week high and low on Friday . The stock traded as low as $104.28 and last traded at $105.18, with a volume of 861246 shares traded. The stock had previously closed at $108.35.
Several research firms recently weighed in on ZBH. SunTrust Banks increased their price objective on shares of Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a research note on Monday, January 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zimmer Biomet in a research note on Friday, January 5th. ValuEngine cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Friday, March 23rd. BMO Capital Markets restated a “buy” rating and issued a $144.00 target price on shares of Zimmer Biomet in a research report on Tuesday, January 30th. Finally, Robert W. Baird restated a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Zimmer Biomet currently has a consensus rating of “Buy” and an average price target of $139.35.
The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.81 and a current ratio of 1.50. The firm has a market cap of $22,010.97, a PE ratio of 13.10, a P/E/G ratio of 1.89 and a beta of 1.17.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 11.96%.
In other news, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $115.95, for a total value of $2,414,774.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bryan C. Hanson acquired 25,077 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was bought at an average price of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. Company insiders own 1.07% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Schroder Investment Management Group lifted its stake in Zimmer Biomet by 41.0% during the third quarter. Schroder Investment Management Group now owns 52,720 shares of the medical equipment provider’s stock valued at $6,098,000 after purchasing an additional 15,320 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in Zimmer Biomet during the third quarter valued at approximately $370,000. Dimensional Fund Advisors LP lifted its stake in Zimmer Biomet by 6.1% during the third quarter. Dimensional Fund Advisors LP now owns 831,017 shares of the medical equipment provider’s stock valued at $97,283,000 after purchasing an additional 47,979 shares during the last quarter. KBC Group NV lifted its stake in Zimmer Biomet by 6.6% during the third quarter. KBC Group NV now owns 21,496 shares of the medical equipment provider’s stock valued at $2,517,000 after purchasing an additional 1,329 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI acquired a new stake in Zimmer Biomet during the third quarter valued at approximately $393,000. Institutional investors and hedge funds own 86.51% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3339904/zimmer-biomet-zbh-sets-new-52-week-high-and-low-at-104-28.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.